While more studies are needed, current evidence supports their potential to reduce CV risk through multiple direct and indirect mechanisms, offering hope for improved outcomes in a population with historically elevated premature mortality
Si bien los agonistas GLP1 son medicamentos seguros, con baja posibilidad de hipoglicemia, sus efectos negativos sobre la motilidad del aparato digestivo generan que los sntomas gastrointestinales sean los efectos adversos ms frecuentes
Which GLP-1 medicines are available in India in 2026
The First Triple G-Agonist In their Nature Medicine editorial this week A Revolution in Obesity Treatment, Lingvay and Agarwal highlighted the results of the first triple incretin-like drugretatrutidewith completed Phase 2 randomized trials
One common question that arises is whether they can safely incorporate supplements into their regimen to support their well-being
Cardioprotective Research (Preclinical) A significant body of preclinical research from Cuban investigators has documented cardioprotective and cytoprotective properties of GHRP-6
